Posted by Michael Wonder on 13 Apr 2021
NMPA approves toripalimab in patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neo-adjuvant or adjuvant platinum-containing chemotherapy
12 April 2021 - Third indication approved for toripalimab in China.
Junshi Biosciences announced today that the National Medical Products Administration of China has granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neo-adjuvant or adjuvant platinum-containing chemotherapy.
